Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IPF Clear all
Recruiting Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT07284602
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Deupirfenidone, Pirfenidone (PFD)
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
16
States / cities
Palm Spring, California • Redding, California • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed No phase listed Observational Results available

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

NCT05779007
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 24, 2026, 4:10 AM EDT
Enrolling by invitation Phase 3 Interventional

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions
Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
1,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
81
States / cities
Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05954988
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
LTI-03, Placebo
Drug
Lead sponsor
Rein Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 24, 2026, 4:10 AM EDT
Completed No phase listed Observational

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

NCT01417520
View directory record Official record
Conditions
Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 24, 2026, 4:10 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01266135
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
QAX576, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Orlando, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

NCT01442779
View directory record Official record
Conditions
Respiratory Tract Diseases, Lung Diseases, Lung Diseases, Interstitial, Pulmonary Fibrosis
Interventions
Interferon alpha oral lozenge
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 24, 2026, 4:10 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

NCT06360094
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
BI 1839100, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Withdrawn No phase listed Observational

Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry

NCT00212511
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device

NCT05670587
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lakewood, Colorado • Reno, Nevada • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 24, 2026, 4:10 AM EDT
Terminated Phase 3 Interventional Results available

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

NCT00768300
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
40 Years to 80 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

NCT02503657
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed No phase listed Observational

Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry

NCT00540475
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
5
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 24, 2026, 4:10 AM EDT
Recruiting Phase 2 Interventional

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Not applicable Interventional

IPF mHealth Exercise Study

NCT04838275
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
12-week mHealth home exercise prescription
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

NCT00600028
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Cough
Interventions
Thalidomide, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 24, 2026, 4:10 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

NCT01629667
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Tralokinumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
50 Years to 79 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • La Jolla, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 24, 2026, 4:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Genetic Factors in the Development of Lung Disease

NCT00001532
View directory record Official record
Conditions
Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma, Pulmonary Sarcoidosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

NCT01262001
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
35 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 24, 2026, 4:10 AM EDT
Suspended Phase 1 Interventional

Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT04643769
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ORIN1001, Placebo
Drug
Lead sponsor
Orinove, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Clearwater, Florida • Jacksonville, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 24, 2026, 4:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327
View directory record Official record
Conditions
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

NCT05671835
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
TTI-101, Placebo
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 4:10 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis

NCT02151435
View directory record Official record
Conditions
IPF
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 24, 2026, 4:10 AM EDT
Not listed No phase listed Observational

Interstitial Lung Disease in Early Rheumatoid Arthritis

NCT03977415
View directory record Official record
Conditions
Rheumatoid Arthritis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 90 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 24, 2026, 4:10 AM EDT